CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 316 enrolled
Drug / intervention
Whole Exome Sequencing (WES)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03482141
NCT03482141N/ACompleted

Clinical Utility of Prenatal Whole Exome Sequencing

University of California, San Francisco·interventional·Posted Mar 29, 2018·Updated Apr 14, 2023

In Brief

A clinical study evaluating Whole Exome Sequencing (WES) for Structural Anomalies and 7 related conditions. Completed, enrolled 316 participants across 1 site.

Detailed Summary

The investigator aims to examine the clinical utility of WES, including assessment of a variety of health-related and reproductive outcomes in undiagnosed prenatal cases.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedMar 29, 2018
Enrollment StartAug 1, 2017
Primary CompletionMay 13, 2022
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 8.3 years ago

Interventions

Whole Exome Sequencing (WES)device

The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.